ENSC: Ensysce Biosciences Inc. Stocks News on September 8, 2025

ENSC

ACCESS Newswire

2 months ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

ENSC

ACCESS Newswire

3 months ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

ENSC

ACCESS Newswire

3 months ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

ENSC

Zacks Small Cap Research

4 months ago

ENSC is Moving Closer to Changing the Pain Relief Market

ENSC

ACCESS Newswire

4 months ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

ENSC

ACCESS Newswire

4 months ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

ENSC

ACCESS Newswire

4 months ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

ENSC

Benzinga

4 months ago

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

ENSC

ACCESS Newswire

4 months ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

ENSC

MT Newswires

4 months ago

Top Midday Gainers

ENSC

MT Newswires

5 months ago

Ensysce Biosciences Gets US Patent for Opioid Use Disorder Treatment; Shares Rise Pre-Bell

ENSC

ACCESS Newswire

5 months ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

ENSC

ACCESS Newswire

5 months ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

ENSC

Zacks Small Cap Research

5 months ago

ENSC Shows Compound Protects Against Abuse

ENSC

ACCESS Newswire

5 months ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ENSC

ACCESS Newswire

6 months ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

ENSC

GlobeNewswire

6 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations

ENSC

Simply Wall St.

6 months ago

Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations

ENSC

Zacks Small Cap Research

6 months ago

ENSC Starts 2025 in Great Shape

ENSC

ACCESS Newswire

6 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

ENSC

ACCESS Newswire

6 months ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

ENSC

PR Newswire

6 months ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

ENSC

ACCESS Newswire

7 months ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

ENSC

Simply Wall St.

7 months ago

When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)?

ENSC

ACCESS Newswire

8 months ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

ENSC

Zacks Small Cap Research

8 months ago

ENSC Continues to Announce Potential Life-Changing Results

ENSC

ACCESSWIRE

8 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

ENSC

MT Newswires

8 months ago

Ensysce Biosciences Regains Full Compliance With Nasdaq Listing Rules

ENSC

ACCESSWIRE

8 months ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

ENSC

ACCESSWIRE

9 months ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

ENSC

ACCESSWIRE

9 months ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

ENSC

ACCESSWIRE

9 months ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

ENSC

ACCESSWIRE

9 months ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations

ENSC

Simply Wall St.

10 months ago

Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations

ENSC

Zacks Small Cap Research

10 months ago

ENSC Improves Position

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

ENSC

ACCESSWIRE

10 months ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

ENSC

ACCESSWIRE

10 months ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

ENSC

MT Newswires

a year ago

Ensysce Biosciences Files For Resale of Up to 29.5 Million Shares by Investors

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

ENSC

MT Newswires

a year ago

Top Midday Decliners

Ensysce Biosciences Receives Notice from Nasdaq

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Receives Notice from Nasdaq

Ensysce Biosciences Presenting at Upcoming Meetings

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Presenting at Upcoming Meetings

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

ENSC

MT Newswires

a year ago

Ensysce Biosciences Prices $5 Million Registered Direct Offering

ENSC

GlobeNewswire

a year ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

ENSC

MT Newswires

a year ago

Ensysce Biosciences Gets $14 Million Federal Grant for Continued Development of Potential Opioid With Overdose Protection -- Shares Soar Pre-Bell

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

ENSC

Zacks Small Cap Research

a year ago

ENSC Treatment Gets Substantial Grant

ENSC

GlobeNewswire

a year ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ENSC

Simply Wall St.

a year ago

Ensysce Biosciences Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ENSC

Zacks Small Cap Research

a year ago

ENSC Furthers Important Drug Research

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Ensysce Biosciences Provides Mid-Year 2024 Update

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Provides Mid-Year 2024 Update

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

ENSC

MT Newswires

a year ago

Ensysce Biosciences Back in Compliance With Nasdaq

Ensysce Biosciences Regains Compliance with Nasdaq

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Regains Compliance with Nasdaq

ENSC

MT Newswires

a year ago

Sector Update: Health Care Stocks Softer Late Afternoon

ENSC

MT Newswires

a year ago

Sector Update: Health Care

ENSC

MT Newswires

a year ago

Ensysce Biosciences Renews Collaboration with Quotient Sciences for Pain Killer Drug Study

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

Ensysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ENSC

Simply Wall St.

a year ago

Ensysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Ensysce Biosciences Reports First Quarter 2024 Financial Results

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Reports First Quarter 2024 Financial Results

ENSC

Zacks Small Cap Research

a year ago

ENSC: Quarterly Report Highlights Progress

Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

ENSC

Zacks Small Cap Research

a year ago

ENSC Striding Toward Opioid Replacement

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

ENSC

ACCESSWIRE

a year ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

ENSC

ACCESSWIRE

2 years ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

ENSC

ACCESSWIRE

2 years ago

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

ENSC

Zacks Small Cap Research

2 years ago

ENSC: Investors Should Pay Attention

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

ENSC

ACCESSWIRE

2 years ago

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

ENSC

ACCESSWIRE

2 years ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

ENSC

ACCESSWIRE

2 years ago

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

ENSC

ACCESSWIRE

2 years ago

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

Generation Income Properties Announces Tax Treatment of 2023 Distributions

ENSC

ACCESSWIRE

2 years ago

Generation Income Properties Announces Tax Treatment of 2023 Distributions

iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member

ENSC

GlobeNewswire

2 years ago

iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

ENSC

GlobeNewswire

2 years ago

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Is It Smart To Buy Southern States Bancshares, Inc. (NASDAQ:SSBK) Before It Goes Ex-Dividend?

ENSC

Simply Wall St.

2 years ago

Is It Smart To Buy Southern States Bancshares, Inc. (NASDAQ:SSBK) Before It Goes Ex-Dividend?

Novagold Resources Inc (TSX:NG) Reports Fiscal Year 2023 Financial Results

ENSC

GuruFocus.com

2 years ago

Novagold Resources Inc (TSX:NG) Reports Fiscal Year 2023 Financial Results

United Security Bancshares (UBFO) Reports Record Net Income for 2023

ENSC

GuruFocus.com

2 years ago

United Security Bancshares (UBFO) Reports Record Net Income for 2023

Signing Day Sports Promotes Holistic Student-Athlete Wellbeing in the Sports Industry

ENSC

GlobeNewswire

2 years ago

Signing Day Sports Promotes Holistic Student-Athlete Wellbeing in the Sports Industry

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

ENSC

ACCESSWIRE

2 years ago

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

Good Times Restaurants to Release First Quarter Financial Results on January 31, 2024

ENSC

Business Wire

2 years ago

Good Times Restaurants to Release First Quarter Financial Results on January 31, 2024

Opioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's Why

ENSC

Benzinga

2 years ago

Opioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's Why

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

ENSC

ACCESSWIRE

2 years ago

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

ENSC

Zacks Small Cap Research

2 years ago

ENSC Announces Major FDA Designation

Kartoon Studios Announces Significant Increase in Content Production Planned for 2024

ENSC

GlobeNewswire

2 years ago

Kartoon Studios Announces Significant Increase in Content Production Planned for 2024

ENSC

GlobeNewswire

2 years ago

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

ENSC

GlobeNewswire

2 years ago

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination

ENSC

PR Newswire

2 years ago

Latest Ensysce Biosciences Inc. (ENSC) News on September 8, 2025

Share on Social Networks: